Axon Enterprise (NASDAQ:AXON) President Joshua Isner Sells 16,775 Shares

Axon Enterprise, Inc (NASDAQ:AXON) President Joshua Isner sold 16,775 shares of Axon Enterprise stock in a transaction on Monday, August 31st. The stock was sold at an average price of $574.43, for a total transaction of $9,636,063.25. Following the sale, the president directly owned 296,974 shares of the company’s stock, valued at $170,590,774.82. This represents a 5.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joshua Isner also recently made the following trade(s):

• On Friday, June 5th, Joshua Isner sold 13,000 shares of Axon Enterprise stock. The shares were sold at an average price of $488.45, for a total value of $6,349,850.00.

Axon Enterprise Trading Down 2.2%

AXON opened at $506.98 on Thursday. The firm’s fifty day moving average is $566.59 and its two-hundred day moving average is $485.27. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.80 and a current ratio of 2.15. The firm has a market cap of $41.19 billion, a PE ratio of 210.37, a price-to-earnings-growth ratio of 8.41 and a beta of 1.40. Axon Enterprise, Inc has a twelve month low of $339.01 and a twelve month high of $792.16.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $1.88 EPS for the quarter, topping analysts’ consensus estimates of $1.84 by $0.04. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%.The company had revenue of $904.39 million for the quarter, compared to analyst estimates of $876.42 million. During the same quarter last year, the firm posted $2.12 earnings per share. Axon Enterprise’s revenue was up 35.3% compared to the same quarter last year. Equities research analysts anticipate that Axon Enterprise, Inc will post 2.04 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on AXON shares. Barclays raised their price target on shares of Axon Enterprise from $523.00 to $688.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Axon Enterprise in a research report on Wednesday, August 5th. Morgan Stanley increased their price objective on shares of Axon Enterprise from $600.00 to $640.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. UBS Group lifted their target price on Axon Enterprise from $440.00 to $600.00 and gave the company a “neutral” rating in a research report on Thursday, August 6th. Finally, Piper Sandler upped their target price on Axon Enterprise from $724.00 to $732.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $730.92.

Institutional Trading of Axon Enterprise

Several institutional investors and hedge funds have recently bought and sold shares of AXON. Creative Financial Designs Inc. ADV bought a new position in shares of Axon Enterprise during the 4th quarter worth approximately $28,000. Keating Financial Advisory Services Inc. acquired a new stake in Axon Enterprise during the 2nd quarter valued at $31,000. AlphaCentric Advisors LLC bought a new position in Axon Enterprise during the fourth quarter worth $34,000. Darwin Wealth Management LLC bought a new position in Axon Enterprise during the second quarter worth $37,000. Finally, Washington Trust Advisors Inc. raised its position in shares of Axon Enterprise by 1,300.0% in the second quarter. Washington Trust Advisors Inc. now owns 70 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 65 shares during the period. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.